Patient Experience Data: Researchers Call for More Consistency From FDA

Researchers at drugmaker Sanofi are calling on the US Food and Drug Administration (FDA) to make its publication of patient experience data (PED) in review documentation more consistent after reviewing applications approved in the first full year after a requirement of the 21st Century Cures Act compelled the agency to do so.